Secondary Objectives: SLN and Injection Site Accumulation During PET/CT and Visualization During Robotic Surgery
| Study one | Study two | Study three | |||||||||||||
| PET/CT | γ-counter | PET/CT | γ-counter | PET/CT | γ-counter | ||||||||||
| Lymph node/injection site | SUV | Satisfy 10% rule? (yes/no) | FireFly in vivo fluorecence? (yes/no) | Percentage injected dose (%) | Dye content (pmol) | SUV | Satisfy 10% rule? (yes/no) | FireFly in vivo fluorescence? (yes/no) | Percentage injected dose (%) | Dye content (pmol) | SUV | Satisfy 10% rule? (yes/no) | FireFly in vivo fluorescence? (yes/no) | Percentage injected dose (%) | Dye content (pmol) |
| L. external iliac | No | No | |||||||||||||
| R. external iliac | No | No | NV | Yes | 0.38 | 8.50 | |||||||||
| Presacral | No | No | No | ||||||||||||
| Para aortic | No | No | No | ||||||||||||
| L. common iliac | No | No | No | ||||||||||||
| R. common iliac | 12.4 | Yes | Yes | 2.72 | 32.3 | No | 139 | Yes | Yes | 1.33 | 29.8 | ||||
| L. perivesicular | No | No | No | ||||||||||||
| R. perivesicular | 59.0 | Yes | Yes | 1.44 | 61.0 | 65.2 | Yes | Yes | 3.91 | 88.0 | No | ||||
| L. pelvic | No | No | No | ||||||||||||
| R. pelvic | No | No | No | ||||||||||||
| L. obturator | No | No | No | ||||||||||||
| R. obturator | No | No | No | ||||||||||||
| Injection site | 2,911 | Yes | 29.2 | 658 | 1,769 | Yes | 16.5 | 371 | 20,322 | Yes | 64.1 | 1,441 | |||
L. = left; R. = right; NV = not visualized by PET/CT.
If PET/CT or γ-counter did not satisfy the 10% rule, all entries for LN are blank.